flipper44
5 minutes ago
Quite a few of these studies have been laying groundwork for introduction of a csf1r inhibitor, in UCLA’s case, Pexidartinib (Brand name Turalio), spore grant. It’s been ten years since they first were going to do this (DCVax + Pexidartinib + pembrolizumab), and it’s hard to imagine Turalio wouldn’